Cantex Pharmaceuticals, Inc. announced today that the Company’s CEO, Stephen Marcus, M.D., will be an expert speaker at 5th Annual Glioblastoma Drug Development Summit, which will be held March 26-28 at the Hilton Boston Logan Airport....
Cantex Pharmaceuticals announced that Stephen Marcus, M.D., Chief Executive Officer, is participating in the BIO CEO & Investor Conference and is conducting one-on-one meetings with registered investors, showcasing the Company's business and clinical development strategy, recent corporate achievements, and anticipated milestones....
Cantex Pharmaceuticals and Michigan Medicine announced today the initiation of a randomized, double-blind, placebo-controlled, multicenter, Phase 3 pivotal clinical trial to evaluate the safety and efficacy of Cantex’s azeliragon in decreasing the incidence of acute kidney injury and other life-threatening complications in patients hospitalized for COVID-19....
Cantex Pharmaceuticals and Allegheny Health Network (AHN), today announced the initiation of a Phase 1/2 study to assess the safety and efficacy of azeliragon in patients refractory to first-line treatment of metastatic pancreatic cancer....
Cantex Pharmaceuticals and Lenox Hill Hospital’s Department of Neurological Surgery announced the initiation of a Phase 2 study to assess the safety and effectiveness of azeliragon in combination with radiation therapy as a treatment for newly diagnosed unmethylated glioblastoma....
Cantex Pharmaceuticals announced today the initiation of a Phase 2 clinical trial to assess the safety and effectiveness of Cantex’s azeliragon combined with stereotactic radiosurgery in patients with brain metastases. ...
Cantex Pharmaceuticals announced the publication in the peer-reviewed journal, npj Breast Cancer, reporting results from in vitro and in vivo models for triple-negative breast cancer showing suppression of metastasis and tumor progression by RAGE inhibition. Cantex’s azeliragon is a RAGE inhibitor that is orally administered and taken once daily....
Cantex Pharmaceuticals, Inc. today announced that it will present at the MedInvest Oncology Investor Conference being held June 21-22, 2023, in Boston, MA. Stephen G. Marcus, M.D. Cantex’s Chief Executive Officer, will present a corporate overview to strategics/big Pharma, VCs, family offices, hedge funds, and government/non-profit grantmakers....
Cantex Pharmaceuticals announced that it obtained an exclusive worldwide license from Georgetown University for intellectual property related to the potential use of azeliragon to treat, prevent or alleviate cancer-treatment related cognitive decline....
Cantex Pharmaceuticals announced today that the USPTO has issued U.S. Patent No. 11,648,235, titled “Treatment of Glioblastoma,” with claims to a method of treating glioblastoma with azeliragon. This patent will expire in 2042....